A Transformative Alliance in Healthcare
In a groundbreaking move, Quest Diagnostics, the global leader in diagnostic information services, and Oxford Immunotec Global PLC, a rapidly expanding diagnostics company, have announced a strategic partnership that will revolutionize the landscape of infectious disease diagnostics.
Expanding Diagnostic Capabilities
This acquisition will incorporate Oxford Immunotec‘s cutting-edge laboratory services into Quest Diagnostics’ comprehensive portfolio. Notably, the T-SPOT®.TB tuberculosis and the Accutix™ tick-borne disease testing services will become part of Quest’s offerings, significantly broadening their diagnostic capabilities.
Long-Term Collaboration for Innovation
Beyond the acquisition, Quest Diagnostics and Oxford Immunotec will embark on a strategic collaboration to drive the continuous advancement of T-SPOT.TB testing in the United States. This partnership will foster innovation and ensure the availability of cutting-edge diagnostic solutions for healthcare professionals and patients.
Commitment to Patient Care
Quest Diagnostics remains committed to providing physicians with a comprehensive range of TB testing options. They will continue to offer QuantiFERON TB blood testing services, ensuring that healthcare providers have access to the most suitable diagnostic tools for their patients.
The Significance of Blood-based TB Testing
Transformative healthcare alliance: Quest Diagnostics and Oxford Immunotec join forces
- Expanded diagnostic capabilities
- Long-term collaboration for innovation
- Commitment to patient care
- Importance of blood-based TB testing
- Shared vision for the future of diagnostics
The T-SPOT.TB test, an interferon-gamma release assay (IGRA), plays a vital role in diagnosing Mycobacterium tuberculosis infection and disease. With an estimated 13 million cases of latent TB in the United States, accurate and reliable testing is crucial for timely diagnosis and effective treatment.
Advantages of Blood-based IGRA TB Testing
Medical associations, including the Infectious Diseases Society of America (IDSA), advocate for blood-based IGRA TB testing over traditional skin testing in specific patient populations. IGRA testing offers greater accuracy and can be performed with a single office visit, providing convenience and efficiency for both healthcare providers and patients.
Quest Diagnostics: Empowering Healthcare through Diagnostics
Quest Diagnostics is renowned for its commitment to empowering individuals to take proactive steps towards improving their health outcomes. With the world’s largest database of clinical lab results, Quest Diagnostics leverages its diagnostic insights to identify and treat diseases, promote healthy behaviors, and enhance healthcare management.
Quest’s Unwavering Dedication
Quest Diagnostics serves a vast population, including one in three adult Americans and half the physicians and hospitals in the United States. Their 45,000 employees are driven by the belief that diagnostic insights, when properly interpreted and applied, can inspire transformative actions that positively impact lives.
Oxford Immunotec: Advancing Diagnostics for Immune-Regulated Conditions
Transformative healthcare alliance: Quest Diagnostics and Oxford Immunotec join forces
- Expanded diagnostic capabilities
- Long-term collaboration for innovation
- Commitment to patient care
- Importance of blood-based TB testing
- Shared vision for the future of diagnostics
Oxford Immunotec Global PLC is a global diagnostics company focused on developing and commercializing innovative tests for immune-regulated conditions. Their flagship product, the T-SPOT.TB test, has gained widespread recognition and approval in over 50 countries, including the United States, Europe, Japan, and China.
Oxford Immunotec’s Global Presence
Headquartered near Oxford, U.K. and in Marlborough, MA, Oxford Immunotec is committed to expanding its global reach and making its diagnostic solutions accessible worldwide.
A Shared Vision for the Future of Diagnostics
This partnership between Quest Diagnostics and Oxford Immunotec represents a shared vision for the future of diagnostics. By combining their expertise and resources, they aim to revolutionize the way infectious diseases are diagnosed and treated, ultimately leading to improved patient outcomes and a healthier society.
